NICECACTUS/GLORY4GAMERS
26.2.2020 14:02:11 CET | Business Wire | Press release
Following the announcement of an initial funding round of €5 million at the end of 2019, Nicecactus has taken yet another step forward in its global development by acquiring Glory4Gamers. The strategic alliance of these two esports experts provides 1 million users with an all-in-one solution, combining knowledge in training and skill development as well as in organizing both online and offline tournaments. Players, partners and B2B customers alike can now benefit from the comprehensive range of services of these two stakeholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005081/en/
Since the end of January 2020, Nicecactus and Glory4Gamers have combined their expertise and solutions with the ambition to further expand internationally. The G4G teams have joined the Nicecactus family to form a 70-person team. They are reinforcing the already successful model of tournaments and competitions with prize money for players of all levels. In addition, the offline B2B event package, which enables brands (sponsors and publishers) to run promotional campaigns among qualified audiences, will be developed to become one of the pillars of the Nicecactus offer.
An all-in-one platform for aspiring champions
Amateur or semi-professional players, members of the Glory4Gamers and nicecactus.gg platforms, will now benefit from a complete solution empowering them with the professional training method they need to reach their full potential and realize their dream of becoming champions. It ranges from tailor-made training sessions (tutorials and drills), to performance assessment and analysis tools, as well as daily competitions with prizes and even networking with professional players in the sector (sponsors, teams) for the most talented of them.
All players are also eligible for the Nicecactus Grassroots Esports Fund, a $1 million grant program, through which they can cover travel and accommodation expenses to participate in bootcamps at professional training locations or tournaments they have qualified for.
“The decision to acquire Glory4Gamers fits perfectly with our strategy to develop and strengthen our unique offer, which encompasses virtually all aspects of esports, from amateurs to semi-professional players, as well as companies wishing to address this highly qualified target audience,” explains Mike Hessabi, Founder & President of Nicecactus.
"The esports market is growing at breakneck speed, and we want more than ever to be at the heart of this ecosystem. Nicecactus approaches esports with an innovative vision and great ambitions. The combination of Glory4Gamers and Nicecactus felt obvious to us, as we have a very aligned vision and complementary skills," adds Cyril Chomette, CEO and Founder of Glory4Gamers.
About Nicecactus:
First ever all-encompassing esports platform, Nicecactus took root in the sun-bathed French Riviera. Its goal is to foster aspiring esports players who wish to unleash their gaming potential and master their game. Nicecactus provides them with a professional training method as well as all the tools they need to fulfill their dream of becoming champions. Players from all over the world are encouraged to give the best out of themselves, through a continued training program, a fined-tuned stats tracking system and the opportunity to compete in tournaments and make some cash out of their passion in a challenging and fun way. Its first-of-its-kind Nicecactus Grassroots Esports Fund rewards the best players for their talent and dedication by connecting them to the professional world. www.nicecactus.gg
About Glory4Gamers:
Founded in 2012, Glory4Gamers is a pioneer in amateur esports. Now the leading organizer of esports tournaments in France and 3rd in Europe, the platform holds more than 2,000 tournaments per month. Through its unique real-time refereeing component, Glory4Gamers promises its users a unique esports experience, in a fun and fair play environment, and with a human support close at hand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005081/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
